Trimethoprim–sulfamethoxazole (TMP–SMX) is a commonly prescribed antimicrobial agent for a wide variety of infections. It is generally well tolerated in a majority of patients; however, serious ...

Sulfamethoxazole 400mg, trimethoprim 80mg; scored tabs. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim blocks the ...

Background The prophylactic use of sulfamethoxazole-trimethoprim (SMX/TMP) can reduce the risk for developing pneumocystis pneumonia in immunosuppressed patients with systemic rheumatic diseases, ...

Prior analyses focused on cyclophosphamide (CYC)-treated patients, but one retrospective study on patients treated with rituximab (RTX) found a reduced frequency of severe infections when trimethoprim ...

Participants and outcomes The RCT included hospitalised patients with documented or highly-probable invasive MRSA infections who were randomised to vancomycin versus trimethoprim-sulfamethoxazole (TMP ...

Background: Guidelines recommend that agents other than vancomycin be considered for some types of infection due to methicillin-resistant Staphylococcus aureus (MRSA) when the minimum inhibitory ...

It is a fixed combination product containing sulfamethoxazole and trimethoprim in 5:1 ratio. Adult- PO- The recommended dose is 2 tablets every 12 hours for a period of 10 to 14 days. Child- The ...

For further clarification, consult your healthcare provider. This medication is a combination of trimethoprim and sulfamethoxazole, prescribed for certain types bacterial infections. It is also ...

A recent study reported encouraging results for initial treatment with intravenous ceftriaxone or meropenem followed by long-term treatment with oral trimethoprim–sulfamethoxazole. However ...

We used decision analysis to model 3 empiric therapies for the treatment of patients seen initially in an outpatient setting. The model was based on a population of patients with cellulitis who ...